Case Control Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Aug 26, 2023; 11(24): 5643-5652
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5643
Table 1 Baseline characteristics of multiple myeloma patients with a reduction rate of monoclonal protein after first and fourth cycles of chemotherapy
CharacteristicC1 reduction rate
P valueC4 reduction rate
P value
< 50
≥ 50
< 75
≥ 75
Age (yr)≤ 0.0010.003
    < 6525562160
    ≥ 6549344043
Gender0.9120.903
    Male36433742
    Female38473946
ISS stage≤ 0.001≤ 0.001
    I539242
    II31342342
    III38173619
DS stage0.0870.783
    I1111
    II720919
    III66705183
GPT0.6570.985
    ≤ 4071855898
    > 403535
GOT0.5100.617
    ≤ 4067845794
    > 407649
CRP0.7040.880
    ≤ 1053624283
    > 1021281920
A/G0.9160.041
    ≤ 0.529361847
    > 0.545544356
LDH0.2150.530
    ≤ 24554734682
    > 24520171521
t(6;14)331.000240.405
t(11;14)221.000130.615
Platelet count≤ 0.001≤ 0.001
    ≥ 10055884598
    < 100192165
Herpes13190.569923
Autotransplantation5200.0065200.020
TC (mmol/L)0.9030.767
    < 5.263765286
    ≥ 5.21114917
TG (mmol/L)0.5460.778
    < 1.7151584167
    ≥ 1.7123322036
P (mmol/L)0.5870.568
    < 1.0717241326
    ≥ 1.0757664877
Table 2 Univariate analysis of progression-free survival and overall survival
Prognostic factorPFS
OS
HR (95%CI)
P value
HR (95%CI)
P value
Age (yr)1.051 (1.031-1.071)≤ 0.0011.034 (1.012-1.055)0.002
Gender1.265 (0.828-1.931)0.2771.412 (0.926-2.152)0.109
Classification1.037 (0.949-1.132)1.0371.093 (0.999-1.196)0.053
ISS stage1.718 (1.247-2.366)0.0012.093 (1.520-2.883)≤ 0.001
DS stage2.094 (1.082-4.054)0.0281.982 (1.015-3.869)0.045
GPT1.011 (1.002-1.021)0.0191.009 (0.999-1.019)0.082
GOT1.022 (1.011-1.033)≤ 0.0011.025 (1.013-1.038)≤ 0.001
CRP1.002 (0.996-1.007)0.5931.002 (0.996-1.008)0.491
A/G1.041 (0.698-1.553)0.8441.149 (0.754-1.751)0.518
LDH1.003 (1.001-1.004)≤ 0.0011.003 (1.002-1.005)≤ 0.001
t(6;14)1.021 (0.319-3.266)0.9721.285 (0.399-4.134)0.674
t(11;14)1.149 (0.281-4.708)0.8471.188 (0.290-4.871)0.811
Platelet count9.604 (4.965-18.578)≤ 0.0018.437 (4.528-15.721)≤ 0.001
Herpes0.821 (0.451-1.495)0.520.908 (0.498-1.653)0.751
Chemotherapy regimen1.005 (0.856-1.180)0.9520.949 (0.795-1.133)0.564
Autotransplantation0.339 (0.137-0.842)0.0200.347 (0.140-0.860)0.022
TC0.773 (0.631-0.947)0.0130.757 (0.617-0.927)0.007
TG0.861 (0.666-1.114)0.2550.846 (0.642-1.113)0.232
P1.143 (0.953-1.370)0.151.113 (0.934-1.325)0.232
C1 reduction rate0.412 (0.325-0.521)≤ 0.0010.438 (0.346-0.554)≤ 0.001
C2 reduction rate0.412 (0.325-0.523)≤ 0.0010.441 (0.351-0.553)≤ 0.001
C3 reduction rate0.390 (0.303-0.501)≤ 0.0010.377 (0.290-0.490)≤ 0.001
C4 reduction rate0.358 (0.283-0.455)≤ 0.0010.345 (0.267-0.445)≤ 0.001
Table 3 Multivariate analysis of progression-free survival
Prognostic factor
HR (95%CI)
P value
Age1.059 (1.033-1.085)≤ 0.001
ISS stage2.136 (1.500-3.041)≤ 0.001
DS stage1.622 (0.264-1.622)0.264
GPT1.017 (0.997-1.036)0.097
GOT1.002 (0.977-1.028)0.857
LDH1.000 (0.997-1.003)0.944
Platelet count1.880 (0.732-4.830)0.189
Maintenance regimen0.410 (0.236-0.710)0.001
Autotransplantation0.201 (0.069-0.583)0.003
TC0.689 (0.533-0.891)0.005
C1 reduction rate0.474 (0.293-0.767)0.002
C2 reduction rate0.792 (0.440-1.427)0.438
C3 reduction rate1.974 (0.921-4.230)0.08
C4 reduction rate0.254 (0.139-0.463)≤ 0.001
Table 4 Multivariate analysis of overall survival
Prognostic factor
HR (95%CI)
P value
ISS stage1.879 (1.315-2.686)0.001
Age1.054 (1.027-1.081)0.024
DS stage1.829 (0.791-4.233)0.158
GOT1.009 (0.988-1.031)0.395
LDH0.998 (0.996-1.001)0.264
Platelet count2.929 (1.269-6.756)0.012
Autotransplantation0.211 (0.069-0.647)0.006
TC0.735 (0.573-0.943)0.016
C1 reduction rate0.868 (0.543-1.387)0.553
C2 reduction rate0.680 (0.386-1.197)0.181
C3 reduction rate1.055 (0.592-1.879)0.856
C4 reduction rate0.608 (0.350-1.058)